Introduction {#Sec1}
============

Annually, over 200 million people undergo major non-cardiac surgery worldwide \[[@CR1]\]. Despite technical improvements and increased patient monitoring, these procedures currently remain associated with high mortality and morbidity. Overall 30-day mortality exceeds 2 %, and reaches 6 % in high-risk populations (e.g. certain vascular populations) \[[@CR2]--[@CR6]\]. Over half of these deaths are attributable to adverse cardiovascular events \[[@CR3], [@CR7]\].

Recognition of an adverse cardiovascular event in the perioperative phase is difficult. Typical anginal symptoms are often masked due of the use of strong analgesics (e.g. opioids), and changes on the electrocardiogram are predominantly subtle or transient \[[@CR3], [@CR6], [@CR8]\]. Moreover, the diagnostic value of cardiac biomarkers such as cardiac troponin and creatine kinase muscle and brain isotype (CK-MB) remains controversial in the perioperative period, since factors such as skeletal muscle damage, inflammation and renal insufficiency interfere with serum levels \[[@CR9]\]. An adequate and timely diagnosis is therefore frequently delayed, and subsequent therapy may not be initiated at all.

In order to improve early recognition of perioperative myocardial injury (PMI), thorough knowledge of its pathophysiological mechanisms is required. In this article we will elaborate these mechanisms, and review the available evidence concerning perioperative myocardial infarction (MI).

Aetiology of PMI {#Sec2}
================

PMI may originate from four distinct pathophysiological mechanisms:I.*MI type I* is caused by fissuring or rupturing of an unstable coronary artery atherosclerotic plaque. Consecutive platelet activation and aggregation causes thrombus formation that occludes the vessel, and induces myocardial ischaemia \[[@CR10]\]. Surgical patients are especially vulnerable to such adverse events due to a hypercoagulable state in a setting of tachycardia, anaemia, intraoperative hypotension, and postoperative hypertension \[[@CR8]\].II.*MI type II* is caused by either a haemodynamic equilibrium disturbance combined with the presence of significant coronary artery disease (CAD), a severe coronary vasospasm, or endothelial dysfunction \[[@CR8]\]. These mechanisms induce a myocardial oxygen supply--demand mismatch that leads to a more generalised type of myocardial ischaemia than type I \[[@CR11]\]. Common perioperative factors that increase myocardial oxygen demand include hypertension, tachycardia and elevated levels of catecholamines \[[@CR8]\]. Decreased myocardial oxygen supply is attributable to blood loss, intraoperative hypotension, anaemia, and/or coronary vasospasm \[[@CR8]\]. Furthermore, an oxygen supply deficit may develop if the coronary collateral blood supply falls short \[[@CR12]\].III.*Non-ischaemic cardiac pathology* \[[@CR8], [@CR10]\]. This group can be subdivided into cardiac dysrhythmias, acute non-ischaemic cardiomyopathies (e.g. cerebrally or stress-induced), and inflammatory and/or infectious processes. Presence of postoperative electrolyte disturbances, inflammation, hypertension and myocardial ischaemia catalyse the commencement of a dysrhythmia \[[@CR13], [@CR14]\]. Non-ischaemic causes other than dysrhythmias are rare, yet can be provoked by certain factors commonly associated with major surgery or trauma (e.g. high stress levels in case of a Takotsubo / stress-induced cardiomyopathy, or a bacteraemia in case of an endocarditis) \[[@CR15], [@CR16]\].IV.*Non-cardiac causes* such as pulmonary embolism (PE). The perioperative phase is associated with prolonged periods of immobilisation in a period of haemodynamic changes. Therefore, ideal circumstances are present for the formation of a venous thromboembolism, and/or a pulmonary embolism \[[@CR17], [@CR18]\]. The incidence of non-cardiac causes other than PE is low, and mainly restricted to certain high-risk patients.

A combination of two or more pathophysiological mechanisms is also possible. For instance, a myocardial oxygen supply--demand mismatch (i.e. type II MI) may lead to increased shear stress of an atherosclerotic plaque that consecutively causes the plaque to fissure or rupture (i.e. type I MI induction) \[[@CR8], [@CR10]\].

Literature {#Sec3}
==========

Angiographic, histological or alternative imaging studies that provide an overview of the prevalence of all four aetiological mechanisms of PMI are currently not available. Therefore, we have to extrapolate data from studies that have focussed on subgroups. Myocardial infarction type I and II will be emphasised, as myocardial ischaemia has been suggested to be the main cause of postoperative morbidity and mortality \[[@CR3], [@CR8]\].

Type I versus type II myocardial infarction {#Sec4}
-------------------------------------------

The incidence of ST-segment elevation myocardial infarction (STEMI) after non-cardiac surgery ranges from 0.06 % to 1.5 %, and is therefore very low \[[@CR11], [@CR19], [@CR20]\]. In contrast, transient periods of ST depression are relatively common, as incidences range from 0.6 % to 50 % (i.e. numbers vary based on study population and the use of continuous or interval ECG monitoring) \[[@CR11], [@CR20], [@CR21]\]. The ST depressions have historically been associated with type II MI, yet -- especially in the perioperative phase---merely provide a suggestion of the underlying pathophysiological mechanism \[[@CR11]\]. Routine postoperative measurement of cardiac biomarkers, which are highly sensitive for myocardial damage and provide a broader diagnostic window than a non-continuous ECG, essentially suffers from the same inability to provide evidence concerning the pathophysiological mechanism \[[@CR19], [@CR22]\].

Four studies were conducted to assess the incidence of the two types of myocardial infarction after surgery: two necropsy studies and two angiographic studies (Table [1](#Tab1){ref-type="table"}). Appraisal of study relevance and validity is shown in Table [2](#Tab2){ref-type="table"}, and the results are shown in Table [3](#Tab3){ref-type="table"}.Table 1Study designDesign 1Design 2Design 3Design 4Method to define MIDawoodNecropsy^a^RetrospectiveAetiologicalCase controlHP^e^CohenNecropsy^b^RetrospectiveAetiologicalCohortHP^e^GualandroIn-vivo^c^ProspectiveAetiologicalCase controlCAG^f,g^BergerIn-vivo ^d^RetrospectiveTherapeuticCohortCAG^h^*MI* Myocardial infarction*CAG* Coronary Angiography*HP* Histopathology^a^Fatal intraoperative MI, or a MI \<30 days after non-cardiac surgery versus fatal non-perioperative MI^b^Fatal postoperative MI ≤72 h after non-cardiac surgery^c^Suspicion of ACS \<30 days after non-cardiac surgery versus non-perioperative ACS versus stable CAD^d^Referred for CAG because of a suspicion of acute coronary syndrome \<7 days after non-cardiac surgery^e^Histopathological evidence of unstable plaque with disruption^f^Complex atherosclerotic plaque morphology based on Goldstein's criteria^g^Ambrose type II eccentric lesions^h^Intracoronary evidence of thrombusTable 2AppraisalGeneralisabilityValidityStudy designDomainDeterminantOutcomeBlindingBaselineStandardRoutine screeningMissing dataDawood+/−+++----+--?Cohen+/−++++--+--?Gualandro+--+++++--+Berger--+------+/−?--?*Study design* Prospective aetiological study (+); retrospective aetiological study (+/−); other (−)*Domain* Patients with a perioperative ACS: \<7 days (+); \>7 days (−)*Determinant* Methods to define type I MI well described: yes (+); no (−)*Outcome* Angiographic or histopathological data well described: yes (+); no (−)*Blinding* Blinding of assessor for clinical characteristics: present (+); absent (−); incomplete documentation (?)*Baseline* Adequate description of angina, relevant comorbidities and prior cardiac adverse events, ECG characteristics, relevant drug use: 4/4 determinants (+); 3 determinants (+/−), \<3 determinants (−)*Standard* Use of angiographic or histopathological data in accordance to objectified principals: yes (+); no (−); insufficient description (?)*Routine screening* Use of routine diagnostic screening (routine ECG assessment, continuous ECG monitoring or routine biomarker assessment) : yes (+); no (−)Missing data \< 10 % (+); \>10 % (−); not mentioned (?)Table 3ResultsClinical signsAngiographic / histopathological dataSample size (n)Clinical signs of MIAnginaSTE-ACSNSTE-ACSAverage time to CAGMultivessel diseaseNo CADMI type IPresence of thrombusDawood42100 %--------95.3 %4.7 %55%^a^28 %Cohen2642.3 %--------88 %11.5 %46%^a^35 %Gualandro120100 %40.7 %5.8 %65.1 %5.5 days--5.8 %45%^b^7 %57 %^c^Berger48100 %100 %68.8 %31.3 %0.5 days87.5 %0 %90%^d^63 %*n* Number of included patients with perioperative MI*MI* Myocardial infarction*STE-ACS* ST-segment-elevation acute coronary syndrome*NSTE-ACS* Non ST-segment-elevation acute coronary syndrome*CAG* Coronary angiography*CAD* Coronary artery disease- Data not available^a^Histopathological evidence of unstable plaque with disruption^b^Ambrose type II eccentric lesions^c^Complex atherosclerotic plaque morphology based on Goldstein's criteria^d^Unknown

*Dawood et al.* \[[@CR23]\] performed a histopathological analysis of coronary arteries and myocardium of autopsy heart specimens of patients who suffered either a fatal perioperative MI (*n* = 42), or a non-perioperative MI (*n* = 25). Patients in the former group were eligible for inclusion if they had suffered an intraoperative MI, or a MI \<30 days of elective or emergency surgery. The latter group was characterised by evidence of MI in a non-surgical phase (i.e. no surgery for at least 3 months prior to their infarction). Diagnostic criteria for MI were based on laboratory biomarkers, clinical parameters (e.g. chest pain and/or pulmonary oedema), and an electrocardiogram (ECG). Histological evidence of plaque rupture and haemorrhage into the plaque cavity or into the lumen was considered direct evidence of disruption of an unstable plaque (type I MI). This was found in 55 % (95 % CI 40--70 %) of patients with a fatal perioperative MI, and in 40 % of patients with a fatal non-perioperative MI. Hence, no significant differences between the two groups were reported regarding type I MI. Intracoronary thrombus was found in 28 %.

*Cohen et al.* \[[@CR24]\] performed a necropsy study that assessed the underlying pathophysiological mechanism of a fatal postoperative MI \<72 h of elective surgery (*n* = 26). The presence of plaque cap fissuring (i.e., disruption of a fibrous cap), plaque haemorrhage, or luminal thrombus containing plaque elements (e.g., cholesterol crystals and lipid-laden macrophages) was considered evidence of plaque rupture (i.e. type I MI). This was present in 46 % (95 % CI 27--67 %) of patients. Thrombus was found in 35 %.

*Gualandro et al.* \[[@CR25]\] performed a prospective angiographic study to assess the cardiac pathophysiological mechanism in 120 patients with a clinical suspicion of acute coronary syndrome (ACS)) within 30 days after non-cardiac surgery. Results were compared with angiographic data from 120 non-surgical patients with spontaneous ACS, and 240 patients with stable CAD. Ambrose type II eccentric lesions (Table [4](#Tab4){ref-type="table"}) and complex morphological features (Table [5](#Tab5){ref-type="table"}) were considered evidence of type I MI \[[@CR26], [@CR27]\]. In the postoperative group, these incidences were 45 % (95 % CI 36--54 %) and 57 % (95 % CI 48-66 %), respectively. These numbers were significantly higher in the non-perioperative ACS group (57 % and 79 %, respectively), and significantly lower in the stable CAD group (16 % and 32 %, respectively). Thrombus was reported in 7.5 %, 32.5 %, and 8.8 % for perioperative ACS, spontaneous ACS, and stable CAD, respectively.Table 4Ambrose criteria \[[@CR26]\]TypeCharacteristicsConcentricSymmetric and smooth narrowingType I eccentricAsymmetric stenosis with smooth borders and a broad neckType II eccentricAsymmetric stenosis in the form of a convex intraluminal obstruction with a narrow neck due to one or more overhanging edges or irregular or scalloped borders, or bothMultiple irregularitiesThree or more serial, closely spaced narrowing or severe diffuse irregularities within a vesselTable 5Criteria for complex lesions - Goldstein et al. \[[@CR27]\]- An intraluminal filling defect consistent with thrombus, defined as abrupt vessel cutoff with persistence of contrast, or an intraluminal filling defect in a vessel within or adjacent to a stenotic region with surrounding homogeneous contrast opacification- Plaque ulceration, defined by the presence of contrast and hazy contour beyond the vessel lumen;- Plaque irregularity (haziness), defined by irregular margins or overhanging edges- Impaired flow (TIMI flow \< 3, except lesions characteristic of chronic total occlusion, identified as tapering lesions with multiple fine collaterals)

*Berger et al.* \[[@CR28]\] performed a retrospective therapeutic study to assess the best immediate intervention in 48 patients referred for coronary angiography because of a suspicion of acute coronary syndrome within 7 days after non-cardiac surgery. All patients had ischaemic chest pain ≥30 min or haemodynamic instability combined with typical ECG changes. Evidence of type I MI was present in 90 % (95 % CI 81 %--98 %) of patients, and intracoronary thrombus was found in 63 %.

### Non-ischaemic cardiac and extra-cardiac pathophysiological mechanisms of PMI {#Sec5}

PMI is not exclusively caused by myocardial infarction. It can also be a result of non-ischaemic cardiac pathology (e.g. dysrhythmias, acute non-ischaemic cardiomyopathies, and inflammatory and/or infectious processes) and/or extracardiac pathology (i.e. predominantly pulmonary embolisms).

Non-ischaemic cardiac pathology {#Sec6}
-------------------------------

The pathophysiology of the non-ischaemic causes of PMI can be subdivided into cardiac dysrhythmias, acute non-ischaemic cardiomyopathies (e.g. cerebrally or stress-induced), and inflammatory and/or infectious processes.

A cardiac dysrhythmia after non-cardiac surgery is a common phenomenon \[[@CR14], [@CR29]\]. Yet, available evidence is predominantly based on retrospective studies using non-continuous ECG monitoring. These studies have designated atrial fibrillation (AF) as the most frequent arrhythmia, affecting an average of 3--4 % of patients undergoing non-cardiac surgery \[[@CR14], [@CR29]\]. An additional 3--4 % develop a supraventricular tachycardia (SVT) other than AF. All dysrhythmias are associated with a worse outcome; a large multicentre trial reported an increased risk of mortality (adjusted odds ratio 1.72; 95 % CI, 1.59--1.86), longer hospital stays (adjusted relative difference, +24.0 %; 95 % CI 21.5--26.5 %), and increased hospitalisation costs (adjusted difference, +\$4177; 95 % CI \$3764--4590). Perioperative mortality directly resulting from a dysrhythmia is seldom reported after non-cardiac surgery, and its incidence is pragmatically believed to be lower than 0.6 % \[[@CR30]\]. Factors associated with an increased risk of developing a perioperative dysrhythmia include age, significant valvular disease, congestive heart failure, prior dysrhythmias, myocardial ischaemia, and electrolyte disturbances \[[@CR14]\]. Also, a (pro-dysrhythmogenic) myocardial contusion should be considered in patients who have experienced blunt thoracic trauma prior to hospitalisation \[[@CR31]\].

A perioperative cerebrally or stress-induced cardiomyopathy can be provoked by an acute cerebrovascular event (predominantly subarachnoid haemorrhage) and/or high preoperative stress levels \[[@CR15], [@CR32]\]. Especially stress-induced cardiomyopathies may clinically present as an acute coronary syndrome, as characteristic ECG signs of a myocardial infarction may be present, and cardiac biomarkers may be elevated \[[@CR33]\]. The incidence of such cardiomyopathies is low, and current evidence mainly consists of case reports \[[@CR15], [@CR32], [@CR34]\].

Postoperative infections and systemic inflammatory response syndromes (SIRS) are a frequent complication of surgery in general \[[@CR16]\]. Yet, inflammation or infection of cardiac structures (i.e. myocarditis, pericarditis or endocarditis) after non-cardiac procedures is rare, and chiefly restricted to patients with prosthetic heart valves \[[@CR35]\]. In those patients, pathogens such as *Staphylococcus aureus* are capable of causing acute valvular failure, which is associated with a very poor prognosis \[[@CR36]\].

Extracardiac pathology {#Sec7}
----------------------

The perioperative phase is associated with prolonged periods of immobilisation and a hypercoagulable state. Therefore, ideal conditions are present for the formation of a venous thromboembolism and a pulmonary embolism (PE). Studies regarding postoperative PE have mainly focussed on orthopaedic and oncological populations, in which the incidence of symptomatic and fatal PE is approximately 1 % and 0.1 %, respectively \[[@CR17], [@CR18], [@CR37]\]. *Asymptomatic* PE is observed in 2--4 %, and is therefore at least twice as common as its symptomatic counterpart \[[@CR38], [@CR39]\]. Of note, these numbers are based on studies using a ventilation/perfusion (V/Q) scan. Using computed tomography pulmonary angiography (CTPA), which has better spatial resolution and diagnostic accuracy than a ventilation-perfusion (V/Q) scan, small (asymptomatic) perfusion defects can be detected more accurately \[[@CR40], [@CR41]\]. If these perfusion defects are taken into account, the incidence of asymptomatic PE after non-cardiac surgery is expected to exceed 4 % \[[@CR37], [@CR42], [@CR43]\]. However, the clinical relevance of small---mostly asymptomatic - perfusion defects has not yet been fully determined \[[@CR44]\].

Other acute extracardiac causes such as a postoperative aortic dissection are very rare after non-cardiac surgery, and should primarily be suspected in patients with relevant extracardiac morbidities, or a high cardiovascular risk profile (e.g. those with a (familial) history of aortic aneurysms/dissections and/or connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome) \[[@CR45]\]. Postoperative hypertension may---in these patients---lead to an increased risk of an aortic dissection \[[@CR45]\].

Discussion {#Sec8}
==========

The incidence of type I MI in patients who suffer a fatal perioperative MI ranges from 45 to 55 % (Table [3](#Tab3){ref-type="table"}). This is not significantly different from the non-surgical patients with fatal MI or sudden cardiac death, in which type I MI represents 50--80 % \[[@CR23], [@CR46], [@CR47]\]. In patients with a clinical suspicion of acute coronary syndrome after non-cardiac surgery, type I MI is observed in 45--57 % (Table [3](#Tab3){ref-type="table"}). This percentage is much higher in patients with a high likelihood of MI, such as patients presenting with ST-elevation ACS \[[@CR28]\]. Of note, the validity and generalisability of these results are retained due a number of limitations (Table [2](#Tab2){ref-type="table"}).

First, the study populations and designs of the aforementioned studies are not interchangeable (Table [1](#Tab1){ref-type="table"}). Dawood studied 42 patients with MI \<30 days of elective or emergency surgery using a case--control design, whilst Cohen studied 26 patients with MI \<72 h after elective surgery using a cohort design. Of note, the study populations and designs of the angiographic studies were even less interchangeable: Gualandro performed a prospective aetiological study that assessed the incidence of type I MI in patients suspected of ACS, whilst Berger performed a retrospective therapeutic study to assess the best immediate invasive strategy in patients with an (almost certain) perioperative MI (Table [1](#Tab1){ref-type="table"}).

Second, the methods to define MI (Table [1](#Tab1){ref-type="table"}) are heterogenic; Dawood and Cohen used a histopathological analysis (i.e. the gold standard), whilst the in-vivo studies used conventional coronary angiography (CAG). A CAG has high diagnostic accuracy for MI, yet a number of limitations have to be recognised \[[@CR48], [@CR49]\]. For instance, its interpretation is primarily based on the assessment of significant coronary lesions. Yet, a significant stenosis is not a necessity for a type I MI, since normal angiographic findings have been reported in 4--31 % of non-surgical patients with acute MI \[[@CR48], [@CR49]\]. In those cases, outward remodelling of an unstable atherosclerotic plaque may have only caused a slight, or even a non-existent coronary lumen reduction \[[@CR50]\]. The share of type I MI may thus be underestimated.

Third, the incidence of clinical signs and symptoms suggestive of MI varies between studies (Table [3](#Tab3){ref-type="table"}); Cohen and Gualandro reported incidences of 42.5 % and 41 %, respectively. Berger reported anginal symptoms in 100 %, and Dawood did not provide any numbers. The high incidence reported by Berger reflects its methodological shortcomings to answer our clinical question. Moreover, it underlines the fact that its population does not fully correspond to the average population with a perioperative MI. The incidences reported by Gualandro appear to be consistent with a large prospective study that reported an incidence of ischaemic symptoms in patients with perioperative non-fatal MI of 38.1 % \[[@CR4]\]. However, Gualandro did not perform routine assessments of cardiac biomarkers and/or continuous ECG monitoring. PMI could therefore have been missed in patients using strong analgesics. As a result, a clinically moderate group was studied, and the incidence of type I may have been overestimated. This suggestion is supported by high numbers of multi- or three-vessel disease (Table [3](#Tab3){ref-type="table"}). Of note, the overestimation may have been somewhat tempered by missing data from critically ill patients who died before the angiography was performed \[[@CR25]\].

Fourth, the incidence of coronary thrombus differs between the angiographic studies; Gualandro reported 7 % compared to 63 % reported by Berger (Table [3](#Tab3){ref-type="table"}). The low incidence found by Gualandro may have been related to the long interval between the MI and the angiography (average delay of 5.5 days versus 0.5 days in Gualandro versus Berger, respectively), the use of statins, antiplatelet and anticoagulant agents, and a lower likelihood of a type I MI than Berger. All of these factors may have contributed to (spontaneous) thrombolysis. The diagnostic delay can be explained by the undesirability of coronary angiography in the (very) early postoperative period, which is a result of its invasive nature, and the necessity of administration of antiplatelet agents and heparin.

Furthermore, the share of non-ischaemic and extracardiac pathology may not be overlooked as a cause of PMI. Especially cardiac dysrhythmias and pulmonary embolisms are common after noncardiac surgery, yet---as with perioperative MI---frequently remain asymptomatic. Current studies tend to be biased toward symptomatic cases that represent a population with a worse prognosis. In case of pulmonary embolisms, this is underlined by a high incidence of impaired right ventricular function, which correlates with a higher risk of death within 3 months (hazard ratio 2.2 (95 % CI 1.4--3.4)) \[[@CR17]\]. Increased accessibility of computed tomography angiography (CTA) will lead to an increased recognition of (asymptomatic) PE \[[@CR51]\]. Yet, the clinical relevance of small asymptomatic perfusion defects detected by CTA is currently unknown and should be evaluated in the near future \[[@CR44]\].

Clinical signs and ECGs cannot guarantee early recognition of PMI, and the implementation of standard continuous ECG monitoring is difficult. Additional screening therefore appears to be indispensable. This creates a window of opportunity for routine postoperative assessment of biomarkers such as cardiac troponin (cTn), which has recently shown to be a strong and independent predictor of short- and intermediate-term mortality \[[@CR3], [@CR19], [@CR22]\]. Its diagnostic interpretation, however, can be troublesome due to the interference of renal dysfunction, cerebral pathology and inflammation \[[@CR9]\]. cTn can therefore not be used as hard evidence of myocardial injury. Yet, it can be used to stratify patients who could benefit from additional anticoagulant therapy or a percutaneous coronary intervention (PE/MI or MI, respectively). Non and minimally invasive modalities (i.e. CTA, MRA and echocardiography) should be accessibly used in the early postoperative phase to avoid the use of superfluous anticoagulant and antiplatelet agents that are a necessity during CAG. The most valuable diagnostic modality should be individually determined based on the patient's type of surgery, medical history, clinical presentation and comorbidities (Table [6](#Tab6){ref-type="table"}).Table 6Useful diagnostic modalities to determine the pathophysiology of PMITypeCharacteristicsCAGProBest diagnostic accuracy for in-vivo assessment of myocardial infarction. Gold standard. Option of immediate assessment of clinical significance of coronary stenoses with FFR. Also, immediate PCI is possibleConInvasive, risk of iatrogenic coronary dissection. Not attractive in the early postoperative phase. Use of contrast fluid. Radiation exposure. ExpensiveIVUSProAssessment of both coronary lumen, and plaque morphology (e.g. atheroma). Assessment of unstable/vulnerable plaques; plaque rupture, erosion, and intracoronary thrombus. Especially useful in situations in which angiographic imaging is considered unreliable, such overlapping vessels that cannot be adequately assessed with CAG, and in case of outward plaque remodellingConExpensive, invasive, time-consuming. Only performed by specialised angiographers. Use of contrast fluid. Radiation exposure. Measurement difficulties in case of bifurcationsOCTProApproximately 10 times higher resolution than IVUS. Well suited for plaque morphologies within 500 μm. Furthermore, similar to IVUSConVessel occlusion by means of gentle balloon inflation, and vessel flushing with saline during imaging acquisition is required. Therefore, assessment of the left main coronary artery might not be desirable. Shallow penetration depth in comparison to IVUS. Not appropriate for evaluation of arterial remodelling. Furthermore, similar to IVUSEchocardiogramProAssessment of myocardial segmental wall kinetics, right ventricular kinetics, and valvular apparatus. No radiation exposureConCoronary and pulmonary arteries no visualised, variable image qualityCCTAProNumber and degree of coronary artery stenoses, coronary calcifications, aspect of coronary plaque. Possibility of obtaining coronary artery calcium scoreConArtefacts due to calcifications. Pulmonary arteries not or only partially visualised. Overestimation of stenosis degree in calcified plaques (blooming). Use of contrast fluid. Radiation exposureCTPAProAssessment of pulmonary arteries. Highly sensitive for PEConDiagnosis of small perfusion defects with unknown prognostic value. Coronaries and heart are not accurately visualised. Use of contrast fluid. Radiation exposureCardiac MRIProHighly sensitive for MI. Assessment of myocardial contraction, and segmental wall kinetics. No radiation exposureConCoronaries and pulmonary arteries not or only partially visualised. Expensive, time-consuming. Use of gadoliniumCardiac adenosine stress MRIProHighly sensitive for MI. Assessment of clinical significance of coronary stenoses by generating chemically-induced myocardial ischaemia.ConCoronaries and pulmonary arteries not or only partially visualised. Expensive, time-consuming. Use of gadolinium. Use of adenosine. Limited availability*PMI* Perioperative Myocardial Injury*CAG* Coronary Angiography*PCI* Percutaneous Coronary Intervention*FFR* Fractional Flow Reserve*IVUS* Intravascular ultrasound*OCT* Optical Coherence Tomography*CCTA* Coronary Computed Tomography Angiography*PE* Pulmonary Embolism*CTPA* Computed Tomography Pulmonary Angiography*MRI* Magnetic Resonance Imaging

Furthermore, the additive value of preoperative cardiac imaging needs to be evaluated, since current clinical prediction models convey prognostic value, yet frequently fail to adequately predict PMI \[[@CR52], [@CR53]\]. Addition of modalities such as a (coronary) CTA may improve prognostic values, and could lead to a better stratification of patients who benefit from additional preoperative or perioperative interventions \[[@CR54]\]. The relevance of such a selection is underlined by the fact that a reduction in cardiac events can be counterbalanced by an increased risk of cerebrovascular pathology or bleeding (e.g. in case of antiplatelet agents) \[[@CR4], [@CR55]\].

Conclusion {#Sec9}
==========

Recognition of perioperative myocardial injury after non-cardiac surgery is difficult due to the masking of angina, and the subtlety or transiency of ECG abnormalities. Thorough knowledge of the pathophysiologic mechanisms is therefore essential. These mechanisms can be subdivided into four groups: type I MI, type II MI, non-ischaemic cardiac pathology, and non-cardiac pathology.

In patients suspected of a perioperative acute coronary syndrome. The incidence of type I MI is 45-57 %; this percentage is higher in those with a high likelihood of MI such as patients with ST-elevation ACS. Of note, the generalisability of this statement is limited due to significant study limitations.

Non-ischaemic cardiac pathology and non-cardiac pathology should not be overlooked as a cause of PMI. Especially pulmonary embolisms and dysrhythmias are a common phenomenon, and may convey important prognostic value. Implementation of routine postoperative troponin assessment and accessible use of minimally invasive imaging should be considered to provide adequate individualised therapy. Also, the addition of preoperative imaging may also improve stratification of high-risk patients that will benefit from pre- or perioperative interventions.
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